MEDICAL COLLEGE OF WISCONSIN

Anita D'Souza discusses ASH 2024 data on multiple myeloma, noting the potential elimination of the 24-hour urine test for clinical trials, the efficacy of teclistamab, daratumumab, and lenalidomide combinations, and the breadth of ongoing research improving patient care.

Anne Sophie Michallet discusses ERADIC trial results comparing MRD-guided therapy with ibrutinib and venetoclax vs standard combination in intermediate-risk CLL, emphasizing defining best patient profile due to potential cardiologic toxicity.

Non-cryopreserved tandem CAR-T therapy showed favorable outcomes in advanced DLBCL, with 75% response rate in a phase 2 trial. Most patients received the therapy within 14 days, highlighting its rapid delivery and potential viability for patients.

Donor search prognosis score equalizes transplant outcomes, enabling quicker HCT with alternative donors for blood cancer patients, as presented at the 2024 ASH Annual Meeting.

Zamto-cel, a non-cryopreserved CD20/CD19 CAR T-cell therapy, demonstrated a 50.8% complete remission rate and 72.8% overall response rate in relapsed/refractory diffuse large B-cell lymphoma patients, with median progression-free survival of 9.0 months. The therapy, delivered fresh without cryopreservation, showed low incidence of severe CRS and ICANS, with no cases of secondary malignancies.

Nurix Therapeutics to host a webcast on Dec 9, 2024, to review Phase 1a/1b clinical trial data of BTK degrader NX-5948, targeting cancer and inflammatory diseases.

Stanford Medicine researchers used a CRISPR-based gene-screening method to identify a gene linked to doxorubicin-induced heart damage, and found a potential drug to protect heart cells.

AI-based protein structure prediction reshapes scientific discovery, with AlphaFold v2 (AF2) accurately predicting specific forms of 99.68% of distinct folds. However, 27.70% of folds have at least one experimental structure over 2.5Å RMSD from AI-predicted structures, highlighting the need for dynamic models to capture protein flexibility essential for critical cellular processes.

BriaCell Therapeutics to present positive survival data for Bria-IMT™ plus immune checkpoint inhibitor in metastatic breast cancer at SABCS® 2024, showing a median overall survival of 13.4 months, a 9.5% objective response rate, and a 55% clinical benefit rate across all breast cancer subtypes.

Lubna Naaz Chaudhary discusses PARSIFAL and Young-PEARL trials, noting no efficacy difference between palbociclib combinations with AI vs SERD in ER+/HER2- metastatic breast cancer. Young-PEARL showed longer progression-free survival with palbociclib plus AI and ovarian suppression over capecitabine, emphasizing the importance of managing AEs. Chaudhary is also involved in ongoing trials evaluating cemiplimab in neoadjuvant settings for triple-negative and ER+/HER2- breast cancer.